<DOC>
	<DOCNO>NCT00003350</DOCNO>
	<brief_summary>Randomized phase III trial compare effectiveness paclitaxel doxorubicin treat patient advance AIDS-related Kaposi 's sarcoma . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether paclitaxel effective doxorubicin treat patient advance AIDS-related Kaposi 's sarcoma</brief_summary>
	<brief_title>Paclitaxel Compared With Doxorubicin Treating Patients With Advanced AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare effect therapy paclitaxel therapy liposomal doxorubicin progression-free survival global assessment quality life subject advance AIDS-related K.S . II . To compare toxicity profile intravenous paclitaxel liposomal doxorubicin patient advance AIDS-related K.S . III . To compare overall complete response rate intravenous paclitaxel liposomal doxorubicin patient advance AIDS-related K.S . IV . To evaluate effect intravenous paclitaxel compare therapy liposomal doxorubicin clinical course HIV infection patient advance AIDS-related K.S. , monitor CD4 CD8 lymphocyte subset , HIV viral load incidence type opportunistic infection . V. To explore relationship viral load response therapy patient AIDS-related K.S . VI . To describe relationship `` technical '' response measure current KS response criterion clinical benefit therapy measure revise KS clinical benefit criterion . OUTLINE : This randomize study . Patients randomize receive either paclitaxel ( arm I ) doxorubicin HCL liposome ( arm II ) . Arm I : Patients receive paclitaxel 3 hour intravenous infusion . Treatment course repeat every 2 week . Patients evaluate every third course . Arm II : Patients receive doxorubicin HCL liposome 30-60 minute intravenous infusion . Treatment course repeat every 3 week . Patients evaluate every odd course . Patients arm continue treatment disease progression unacceptable toxicity . Patients complete response continue study treatment 2 course beyond documented complete response . Quality life assess , , treatment . Patients follow every 3 month first 2 year , every 6 month year 2-5 , annually thereafter . PROJECTED ACCRUAL : There 240 patient ( 120 patient arm ) accrue study 24 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>AIDS-Related Opportunistic Infections</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Serologic diagnosis HIV infection document positive ELISA confirm western blot , federally approve HIV diagnostic test , HIV viral load measurement Biopsyproven , measurable Kaposi 's sarcoma following : Progressive cutaneous disease Symptomatic oropharyngeal conjunctival lesion Any visceral involvement Tumorrelated lymphedema Tumorrelated ulceration pain NOTE : All patient must measurable disease ; baseline measurement must obtain &lt; 4 week prior registration ECOG performance status 02 ANC &gt; = 1000/mm³ ( without use colonystimulating factor ) Platelet count &gt; = 50,000/mm³ Hemoglobin &gt; = 8 gm/dL Bilirubin &lt; 1.5 x upper limit normal ( unless elevation due Crixivan administration isolate elevation conjugate bilirubin ) SGOT SGPT = &lt; 5 x upper limit normal Creatinine = &lt; 2.1 mg/dl Women must pregnant lactate due potential toxicity therapy Women childbearing potential sexually active men must advise use accept effective method contraception due potential toxicity therapy No prior systemic cytotoxic chemotherapy Kaposi 's sarcoma Prior radiation therapy must discontinue &gt; = 7 day prior randomization must NOT deliver marker lesion ; ( NOTE : Radiation therapy permit study treatment ) No active , untreated infection ( new opportunistic infectious complication within previous week require change antibiotic ) ; maintenance therapy opportunistic infection allow No prior concomitant malignancy curatively treat carcinoma situ cervix basal/squamous cell carcinoma skin No neuropsychiatric history alter mental status might prevent informed consent affect ability patient comply study Institutions must ask patient participate quality life portion protocol ; however , patient may decline participation component study still eligible ; reason refusal inability complete QOL assessment must document Assessment Compliance Form ( # 596 ) Must know sensitive E. coli derive proteins No history cardiac insufficiency ( NY Heart Association status &gt; = 2 ) Patients must stable ( change drug dos ) antiretroviral therapy great 14 day prior study ; combination regimen require ; ideally protease inhibitor contain triple therapy regimen Patients must give sign , write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>